Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Dugo M, Huang CS, Egle D, Bermejo B, Seitz RS, Nielsen TJ, Zamagni C, Thill M, Antón-Torres A, Russo S, Sevillano E, Ciruelos EM, Schweitzer BL, Galbardi B, Greil R, Semiglazov V, Colleoni M, Kelly CM, Del Mastro L, Mariani G, Viale G, Győrffy B, Ali HR, Pusztai L, Viale G, Callari M, Gianni L, Bianchini G

Open source

DOI: 10.1016/j.annonc.2026.05.694
Published: 2026 Sep
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.05.694,
  title = {Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.},
  author = {Dugo M and Huang CS and Egle D and Bermejo B and Seitz RS and Nielsen TJ and Zamagni C and Thill M and Antón-Torres A and Russo S and Sevillano E and Ciruelos EM and Schweitzer BL and Galbardi B and Greil R and Semiglazov V and Colleoni M and Kelly CM and Del Mastro L and Mariani G and Viale G and Győrffy B and Ali HR and Pusztai L and Viale G and Callari M and Gianni L and Bianchini G},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.05.694},
  url = {https://doi.org/10.1016/j.annonc.2026.05.694}
}

RIS

TY  - JOUR
TI  - Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
AU  - Dugo M
AU  - Huang CS
AU  - Egle D
AU  - Bermejo B
AU  - Seitz RS
AU  - Nielsen TJ
AU  - Zamagni C
AU  - Thill M
AU  - Antón-Torres A
AU  - Russo S
AU  - Sevillano E
AU  - Ciruelos EM
AU  - Schweitzer BL
AU  - Galbardi B
AU  - Greil R
AU  - Semiglazov V
AU  - Colleoni M
AU  - Kelly CM
AU  - Del Mastro L
AU  - Mariani G
AU  - Viale G
AU  - Győrffy B
AU  - Ali HR
AU  - Pusztai L
AU  - Viale G
AU  - Callari M
AU  - Gianni L
AU  - Bianchini G
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.05.694
UR  - https://doi.org/10.1016/j.annonc.2026.05.694
ER  -

APA

M, D., CS, H., D, E., B, B., RS, S., TJ, N., C, Z., M, T., A, A., S, R., E, S., EM, C., BL, S., B, G., R, G., V, S., M, C., CM, K., L, D. M., G, M., G, V., B, G., HR, A., L, P., G, V., M, C., L, G., & G, B. (2026). Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.05.694

Source records

pubmed · retrieved 2026-09-26T12:31:08.412Z